Growth Opportunities of North American Drug Delivery Technologies Market

Factors such as rising prevalence of chronic diseases, growth in the biologics market, funding initiatives for drug delivery research, and technological advancements are driving the growth of this market.

The North American Drug Delivery Technologies Market is projected to reach USD 758.7 Billion by 2021 from USD 520.0 Billion in 2016, at a CAGR of 6.5%.

In this report, the North American drug delivery technologies market is segmented on the basis of route of administration, end user, and region. Based on end user, the market is segmented into hospitals, ambulatory surgical centers (ASCs)/clinics, home care settings, and other end users. The home care settings segment is expected to register the highest CAGR during the forecast period. Improving patient acceptability, patient awareness, and the need for comfortable usability have increased the use of drug delivery systems in home care settings, thus contributing to the growth of this end-user segment.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1209

Market Drivers: -
                    1 Rising Prevalence of Chronic Diseases
                    2 Launch of New Products in the Market
                    3 Technological Advancements
                    4 Growth in the Biologics Market
                    5 Funding Initiatives for Drug Delivery Research

Based on route of administration, the North American drug delivery technologies market is segmented into oral, pulmonary, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. The topical drug delivery market is expected to grow at the highest CAGR during the forecast period. The high growth in this segment is attributed to the advantages of topical drugs, such as convenience and ease of use, painless application of the correct dosage at the affected site, noninvasive nature, superior spreadability, and enhanced patient compliance.

The North American drug delivery technologies market is divided into two country-level segments, namely, the U.S. and Canada. The U.S. is expected to continue to dominate the market during the forecast period. The large share of the U.S. in the North American market can primarily be attributed to factors such as the rising prevalence of chronic diseases; rapid growth in the geriatric population; growth in the biologics market; and increasing number of regulatory approvals, new product launches, and technological advancements.

Read More: - https://www.marketsandmarkets.com/PressReleases/north-american-drug-delivery-technologies.asp

Key Players:-
The North American drug delivery technologies market is a highly competitive market with the presence of several big and emerging players. Moreover, each product segment has a different set of vendors. Johnson & Johnson, Inc. (U.S.), Novartis AG (Switzerland), F. Hoffman-La-Roche Ltd. (Switzerland), Bayer AG (Germany), Pfizer, Inc. (U.S.), 3M Company (U.S.), Becton, Dickinson and Company (U.S.), Merck & Co, Inc. (U.S.), Sanofi (France), Antares Pharma, Inc. (U.S.), and GlaxoSmithKline Plc. (U.K.) are some of the prominent players in the North American drug delivery technologies market.

The U.S. to Witness High Growth in the North American Drug Delivery Technologies Market

The  research report "North American Drug Delivery Technologies Market by Route of Administration (Oral (Solid), Pulmonary (Nebulizer), Injectable (Device), Ocular (Device), Nasal (Drop), Topical (Solid), Implantable (Active)), End User (Hospital, Home Care) - Global Forecast to 2021", The North American drug delivery technologies market is projected to reach USD 758.7 Billion by 2021 from USD 520.0 Billion in 2016, at a CAGR of 6.5%. Factors such as rising prevalence of chronic diseases, growth in the biologics market, funding initiatives for drug delivery research, and technological advancements are driving the growth of this market.

Know more Insights of  North American Drug Delivery Technologies Market.



In this report, the North American drug delivery technologies market is segmented on the basis of route of administration, end user, and region. Based on end user, the market is segmented into hospitals, ambulatory surgical centers (ASCs)/clinics, home care settings, and other end users. The home care settings segment is expected to register the highest CAGR during the forecast period. Improving patient acceptability, patient awareness, and the need for comfortable usability have increased the use of drug delivery systems in home care settings, thus contributing to the growth of this end-user segment.
 

Topical Drug Delivery to Offer Lucrative Growth Opportunities for Players Operating in the North American Drug Delivery Technologies Market

The topical drug delivery market is expected to grow at the highest CAGR during the forecast period. The high growth in this segment is attributed to the advantages of topical drugs, such convenience and ease of use, painless application of correct dosages at the affected site, noninvasive nature, superior spreadability, and enhanced patient compliance.

 

The growth in the North American Drug Delivery Technologies Market is majorly driven by factors such as rising prevalence of chronic diseases, growth in the biologics market, funding initiatives for drug delivery research, and technological advancements. Prominent players in this market are focusing on new product launches and approvals, acquisitions, collaborations, and expansions to strengthen their market share. 

Based on route of administration, the North American drug delivery technologies market is segmented into oral, pulmonary, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. 

Request for Free Sample Report @  

https://www.marketsandmarkets.com/requestsample.asp?id=1209

 On the basis of type, the oral drug delivery technologies market is segmented into solid, liquid, and semi-solid drug delivery. Solid oral drug delivery is segmented into tablets, capsules, pills, and powders. In 2016, tablets are estimated to account for the largest share of the solid oral drug delivery market. High patient compliance and acceptability are the major factors driving the growth of this market segment.

Based on type, the injectable drug delivery market is segmented into two broad categories, namely, devices and formulations. Devices are further segmented into conventional and self-injectors, while formulations are further categorized into conventional, novel, and long-acting. In 2016, novel drug delivery formulations are expected to account for the largest share of the formulations market. Enhanced efficacy, increased patient compliance by decreasing dose frequency, and targeted drug delivery (which reduces side effects) are some of the key factors driving the growth of this market segment.

On the basis of end users, the drug delivery technologies market in North America is segmented into hospitals, ambulatory surgical centers (ASCs)/clinics, home care settings, and other end users. The home care settings segment is expected to register the highest CAGR during the forecast period. Improving patient acceptability, patient awareness, and the need for comfortable usability has increased the use of drug delivery systems in home care settings, thus creating an array of opportunities for growth in this market segment.